Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Oncovin
gptkb:anaplastic_lymphoma |
| gptkbp:appointed_by |
gptkb:hospital
intravenous infusion hospital or outpatient setting |
| gptkbp:can_be_used_with |
radiation therapy
other chemotherapy agents |
| gptkbp:caused_by |
gptkb:fandom
thrombocytopenia infection risk neutropenia |
| gptkbp:developed_by |
medical researchers
|
| gptkbp:duration |
typically 3 to 6 cycles
|
| gptkbp:first_introduced |
the 1980s
|
| gptkbp:frequency |
every 21 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
ICE regimen
|
| gptkbp:includes |
gptkb:Carboplatin
Etoposide Ifosfamide |
| gptkbp:is_associated_with |
improved survival rates
|
| gptkbp:is_considered |
a combination chemotherapy regimen
standard treatment for certain cancers |
| gptkbp:is_discussed_in |
oncology literature
|
| gptkbp:is_evaluated_by |
clinical trials
efficacy in clinical studies |
| gptkbp:is_monitored_by |
adverse effects
response to treatment |
| gptkbp:is_often_used_in |
treatment of non-Hodgkin lymphoma
treatment of germ cell tumors treatment of sarcomas treatment of testicular cancer |
| gptkbp:is_part_of |
clinical pathways for cancer treatment
multimodal cancer treatment |
| gptkbp:is_subject_to |
guidelines from oncology societies
|
| gptkbp:is_used_for |
treatment of cancer
|
| gptkbp:is_used_in |
pediatric oncology in some cases
|
| gptkbp:requires |
informed consent
nutritional support antiemetic medications growth factor support hydration during treatment monitoring of blood counts |
| gptkbp:side_effect |
fatigue
nausea vomiting hair loss low blood cell counts |
| gptkbp:succeeded_by |
varies by cancer type
|
| gptkbp:suitable_for |
pregnant women
patients with severe liver impairment patients with active infections elderly patients with comorbidities patients with previous severe allergic reactions to components patients with severe kidney impairment patients with uncontrolled comorbidities |